OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Neurodegeneration is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances	578
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease	442
Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease	208
The role of TDP-43 mislocalization in amyotrophic lateral sclerosis	191
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies	116
Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration	114
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease	109
Neuropathology and molecular diagnosis of Synucleinopathies	108
APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease	105
Tauopathies: new perspectives and challenges	104
TDP-43 Pathology in Alzheimer’s Disease	103
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics	100
Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery	99
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis	98
Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease	98
Plaque associated microglia hyper-secrete extracellular vesicles and accelerate tau propagation in a humanized APP mouse model	97
Microbiota in neuroinflammation and synaptic dysfunction: a focus on Alzheimer’s disease	96
“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies	95
Cellular and pathological heterogeneity of primary tauopathies	94
Solving neurodegeneration: common mechanisms and strategies for new treatments	93
New approaches to symptomatic treatments for Alzheimer’s disease	92
Comprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry	91
METTL3-dependent RNA m6A dysregulation contributes to neurodegeneration in Alzheimer’s disease through aberrant cell cycle events	87
Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer’s disease: a systematic review of symptom-general and –specific lesion patterns	82
Post-infection cognitive impairments in a cohort of elderly patients with COVID-19	81

Glycosphingolipids and neuroinflammation in Parkinson’s disease	77
Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology	76
Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination	75
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases	72
Microbial-derived metabolites as a risk factor of age-related cognitive decline and dementia	69
Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers	69
Plaque-associated human microglia accumulate lipid droplets in a chimeric model of Alzheimer’s disease	68
P2RX7 inhibitor suppresses exosome secretion and disease phenotype in P301S tau transgenic mice	68
Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions	64
Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders	58
Constitutively active SARM1 variants that induce neuropathy are enriched in ALS patients	58
Microbial involvement in Alzheimer disease development and progression	57
Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson’s disease brain	55
The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives	55
Adult-onset CNS myelin sulfatide deficiency is sufficient to cause Alzheimer’s disease-like neuroinflammation and cognitive impairment	54
Impaired NHEJ repair in amyotrophic lateral sclerosis is associated with TDP-43 mutations	52
The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored	51
The role of inflammasomes in vascular cognitive impairment	50
The Alzheimer’s disease-associated protective Plcγ2-P522R variant promotes immune functions	49
Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer’s disease brain	48
The CD33 short isoform is a gain-of-function variant that enhances Aβ1–42 phagocytosis in microglia	47
Clusterin secreted from astrocyte promotes excitatory synaptic transmission and ameliorates Alzheimer’s disease neuropathology	47